Sanofi

Aventis Pharma S.a.

Hervé Bouchard

Augustin Hittinger

Francis Blanche

Béatrice Cameron

Tarik Dabdoubi

Michel Tabart

Alain Commercon

Frank Halley

Jidong Zhang

Catherine Souaille

Ravi V J Chari

Serge Mignani

Hartmut Strobel

Daniel J Tavares

Jean Bouquerel

Fabrice Viviani

Daniel Achard

Jean-Dominique Bourzat

Kurt Ritter

Marc Capet

Jean-Luc Malleron

Dominique Lesuisse

Sven Ruf

Patrick Mailliet

Youssef El-Ahmad

Antony Bigot

Vincent Mikol

Marcel Patek

Pascal Desmazeau

Bruno Filoche

Bruno Filoche-Romme

Stefan Guessregen

Conception Nemecek

Jacques Mauger

Fabienne Thompson

Serge Grisoni

Anil Nair

Francois Clerc

Bernard Baudoin

Michael R Myers

Fabienne Parker

Ingrid Sassoon

Claudia Fromond

Marie-Priscille Brun

Alexey Rak

Stéphanie Decary

Paul Ferrari

Pierre-Francois Berne

Laurence Gauzy-Lazo

Philippe Hubert

Marie-Pierre Cherrier

Alain Commerçon

Odile Angouillant-Boniface

Didier Benard

Laurence Gauzy

Thomas Faitg

François Clerc

Alain Le Brun

Yonghong Deng

Daniel Bond

Greg Harlow

Teresa Damiano

Serg Grisoni

Anne Lebrun

Fahad Al-Obeidi

Ravi VJ Chari

Pierre-François Berne

Alain COMMERÇON

Wei Li

Robert Zhao

Chari VJ Ravi

Mark Palermo

Michael Myers

The present disclosure relates, inter alia, to cryptophycin conjugates of formula (V):

Cryptophycin antibody conjugates for the treatment of cancer

Disclosed are antibodies which bind human andCEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding the antibodies. Also disclosed are immunoconjugates comprising the antibodies conjugated or linked to a growth-inhibitory agent, and pharmaceutical compositions comprising the antibodies or immunoconjugates of the invention. The antibodies or immunoconjugates are used for the treatment of cancer or for diagnostic purposes.

Anti-CEACAM5 antibodies and uses thereof

The present disclosure relates to compounds of formula (V): wherein Ab represents an antibody. The disclosure also relates to cryptophycin payloads, as well as to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The disclosure also relates to the process for preparing these conjugates.

The present invention relates to cryptophycin compounds of formula (I). The invention also relates to cryptophycin payloads, to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The invention also relates to the process for preparing these conjugates. 

Cryptophycin compounds and conjugates, their preparation and their therapeutic use

Antibodies are provided which bind human andCEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding the antibodies. Also provided are immunoconjugates comprising the antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising the antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates are used for the treatment of cancer or for diagnostic purposes.

The present invention discloses antibodies which bind human andCEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies. The invention also discloses immunoconjugates comprising said antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates of the invention are used for the treatment of cancer or for diagnostic purposes.

Provided herein are cryptophycin conjugates and compositions containing them. Methods of making and using such compounds also are provided.

Conjugates, preparation thereof, and therapeutic use thereof

The invention relates to novel tomaymicine derivatives comprising a linker. It also relates to the conjugate molecules that comprise one or more of said tomaymicine derivatives covalently linked to a cell binding agent through a linking group that is present on the linker of the tomaymycin derivative. It also relates to the preparation of the tomaymicine derivatives and of the conjugate molecules.

Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use

The invention relates to compounds of formula (I): in which R1, R2, L, X, R3, A, R4, R', R&#x2033;, R&#x2033;&#x2032;, R5, Y and Lare as herein defined, salts and prodrugs thereof, to their use as protein kinase inhibitors, and to methods of treating diseases comprising adminstration thereof.

Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors

Disclosed are novel substituted indazole compounds, pharmaceutical compositions comprising such compounds, and methods of treatment comprising such compounds.

Substituted indazoles, compositions containing the same, and the preparation and use thereof

Substituted tetrahydro-1H-pyrazolo[3,4-c]pyridines, compositions comprising them and use. The present invention relates in particular to novel substituted tetrahydro-1H-pyrazolo[3,4-c]pyridines having therapeutic activity, which can be used in particular in oncology. 

Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use

New taxoids of general formula (I), their preparation and pharmaceutical compositions containing them. In general formula (I), The new products of general formula (I) have a remarkable antitumor activity. 

Taxoids, their preparation and pharmaceutical composition containing them

The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.

Chemical derivatives and their application as antitelomerase agent

A method of treating or preventing obesity, this method comprising administering to a patient in need of such treatment an effective amount of a compound of formulain which R, Rand Rare as defined in the specification.

Pharmacological uses of azetidine derivatives

Disclosed are azetidine derivatives of formula:their optical isomers, their salts, their preparation and medicaments containing them.

Acetindine derivatives, their preparation and medicaments containing them

Growing community of inventors

Thiais, France

Hervé Bouchard